Why Vector Yield Remains The Biggest Bottleneck In Vivo Gene Therapy

During this first segment of Cell & Gene Live, Solving Vector Yield Challenges in In Vivo CGT, Karen Kozarsky, Ph.D., President and CSO of Vector BioPartners, and Robert Bell, Ph.D., CSO of Ascidian Therapeutics, define the industry's biggest challenge in balancing biological performance with manufacturability. The conversation explores why vector yield remains a persistent bottleneck, how demand has outpaced manufacturing capabilities, and why developers must address efficacy and scalability simultaneously from the earliest stages of development.